logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Primary Insomnia

    Medications for Primary Insomnia

    FiltersReset Filters
    11 results

    • ambien

      (zolpidem tartrate)
      sanofi-aventis U.S. LLC
      Usage: AMBIEN (zolpidem tartrate) is indicated for the short-term treatment of insomnia, specifically for difficulties with sleep initiation. It effectively reduces sleep latency for up to 35 days, as demonstrated in controlled clinical studies lasting 4–5 weeks.

    • ambien

      (zolpidem tartrate)
      sanofi-aventis U.S. LLC
      Usage: AMBIEN CR (zolpidem tartrate extended-release tablets) is indicated for the short-term treatment of insomnia, particularly for difficulties with sleep onset and/or maintenance, as measured by wake time after sleep onset. Clinical trials supporting its efficacy lasted up to 24 weeks.

    • belsomra

      (suvorexant)
      Merck Sharp & Dohme LLC
      Usage: BELSOMRA® (suvorexant) is indicated for treating insomnia, specifically for individuals who have trouble with sleep onset and/or sleep maintenance.

    • dayvigo

      (lemborexant)
      Eisai Inc.
      Usage: DAYVIGO is indicated for the treatment of adult patients with insomnia, specifically for those experiencing difficulties with sleep onset and/or sleep maintenance.

    • doxepin

      (Doxepin)
      North Star Rx LLC
      Usage: Doxepin tablets are indicated for treating insomnia, specifically for individuals experiencing difficulty with sleep maintenance, based on clinical trials lasting up to 3 months.

    • eszopiclone

      (Eszopiclone)
      Teva Pharmaceuticals USA, Inc.
      Usage: Eszopiclone tablets are indicated for the treatment of insomnia, as they have been shown to decrease sleep latency and improve sleep maintenance in clinical studies lasting up to 6 months.

    • halcion

      (triazolam)
      Pharmacia & Upjohn Company LLC
      Usage: Halcion is indicated for the short-term treatment of insomnia in adults, typically for a duration of 7 to 10 days.

    • quviviq

      (Daridorexant)
      Idorsia Pharmaceuticals Ltd
      Usage: QUVIVIQ is indicated for the treatment of insomnia in adult patients, specifically addressing issues with sleep onset and/or sleep maintenance.

    • silenor

      (doxepin hydrochloride)
      Currax Pharmaceuticals LLC
      Usage: SILENOR is indicated for the treatment of insomnia characterized by difficulty maintaining sleep, with clinical trials supporting its efficacy for up to 3 months.

    • triazolam

      (triazolam)
      Greenstone LLC
      Usage: Triazolam is indicated for the short-term treatment of insomnia in adults, typically for a duration of 7 to 10 days.